The Multibiomarker Acro-TIME Score Predicts First-generation Somatostatin Receptor Ligands (fg-SRLs) Response: Preliminary Results of a Retrospective Acromegaly Cohort
Authors' conclusion
Although our predictive model should be validated in prospective studies, our data suggest that this nomogram may represent an easy to use tool for predicting the fg-SRL outcome early.
Study context
- Population
- Medically naïve patients with acromegaly treated with first-generation SRLs (fg-SRLs)
- Participants
- 67 patients
- Outcome
- Prognostic model (nomogram) predicting fg-SRL response from clinical, biochemical, pathological features incl. immune tumor microenvironment
Methodological detailsmonocenter, univariable and multivariable logistic regression, stepwise selection, nomogram
- Monocenter
- Univariable and multivariable logistic regression
- Stepwise selection
- Nomogram
Main finding
As reported in the abstract
- fg-SRL responders
- 37 patients
- Absent/cytoplasmatic SSTR2 expression, poor response: OR
- 5.493 (95% CI 1.19-25.16, P = .028)
- Low CD68+/CD8+ ratio, poor response: OR
- 1.162 (95% CI 1.01-1.33, P = .032)
- Radical surgical resection, poor response: OR
- 0.106 (95% CI 0.025-0.447, P = .002)
- Nomogram (CD68+/CD8+ ratio, SSTR2 score, postsurgery residual tumor) AUC
- 0.85
Observational data: associations, not effects.
Original publication
The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort. J Clin Endocrinol Metab. Published 17 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →